Publications
- Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed2017 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Science
- G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy2016 | Faculty of Medicine in Pilsen
- Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation2015 | Faculty of Medicine in Pilsen, Faculty of Science
- The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study2015 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Predictive and Prognostic Significance of Sodium Levels in Patients with NSCLC Treated by Erlotinib2014 | Faculty of Medicine in Pilsen
- Sera and plasma biomarkers in colorectal carcinoma2013 | Faculty of Medicine in Pilsen
- KRAS (G12S) mutation in a patient with NSCLC treated with erlotinib – a case report2013 | Faculty of Medicine in Pilsen
Loading network view...
